Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot Study

  • End date
    Jan 1, 2023
  • participants needed
  • sponsor
    Ain Shams University
Updated on 25 January 2022
motor symptoms
antiparkinsonian agents


Zonisamide (ZNS) (1,2-Benzisoxazole-3-methanesulfonamide) is an anti-epileptic drug. In three double blinded placebo controlled studies, ZNS- as an adjunctive treatment- showed beneficial effects on motor symptoms of PD with a low incidence of adverse events. As a result 25 mg daily of ZNS was approved in 2009 in Japan as an adjunctive treatment in PD patients whose condition responded insufficiently to Levodopa treatment.

Most observations of a beneficial effect of ZNS have been in Japanese people, and the antiparkinsonian mechanism of action is unclear. So, ZNS is a promising but still investigational drug to treat PD and more studies are warranted.

this study will investigate the efficacy and tolerability of Zonisamide as an adjunctive treatment in Egyptian patients with advanced PD, including motor fluctuations, levodopa induced dyskinesia and existing nonmotor symptoms. Additionally it investigates its effects on quality of life of PD patients.


Type of Study: Randomized double blinded Placebo controlled study.

  • Study Setting: Movement disorders clinic of neurology department, Ain Shams University Hospitals.
  • Study Period : 2 years.
  • Study Population: Patients with advanced PD and insufficient response to dopaminergic drugs .

Inclusion Criteria:

  • Age older than 18 years of both male and female genders.
  • Individuals diagnosed with PD based on the presence of 2 of 3 cardinal features & United Kingdom bank criteria for idiopathic Parkinson's disease.
  • Patients with manifestations of advanced PD defined according to the consensus on the definition of advanced PD.
  • Inadequate response to dopaminergic medications due to limitations related to side effects, or levodopa related long-term problems as wearing-off phenomena, "on"-"off" fluctuation, levodopa induced dyskinesia and freezing phenomena, no-"on" and delayed-"on,".

Exclusion Criteria:

  1. Patients with atypical or secondary parkinsonian syndromes excluding PD.
  2. Patients who could not perform the tests.
  3. Women who were or might be pregnant, who did not practice effective contraception and were of childbearing potential, or who were breastfeeding.

Ethical Considerations:

All of the patients will be informed of the objectives, procedures and possible benefits and risks of the study and will provide written voluntary consent.

The study will conform to the standards of the Ethical Review Committee, Ain Shams University.

Study Procedures:

  • Patients diagnosed with PD will be evaluated for inclusion and exclusion criteria. Eligible patients will be randomly assigned to one of three groups: placebo group , ZNS group 25 mg and ZNS group 50 mg (30 patients each).In ZNS 50 mg group, ZNS will be started with a dose of 25 mg daily for one week then increased to 50 mg once daily to minimize side effects. The dosage and regimen of ongoing antiparkinsonian drugs and other drugs that may affect PD symptoms will remain unchanged one month before and through the treatment period.

Condition Parkinson Disease
Treatment Zonisamide Capsules
Clinical Study IdentifierNCT04182399
SponsorAin Shams University
Last Modified on25 January 2022


Yes No Not Sure

Inclusion Criteria

-Age older than 18 years of both male and female genders. 2-Individuals
diagnosed with PD based on the presence of 2 of 3 cardinal features & UK bank
criteria for idiopathic Parkinson's disease. 3-Patients with motor
complications of PD (Hoehn and Yahr stage 2-3)(on therapy) and at least 2
hours off time

Exclusion Criteria

-Patients with atypical or secondary Parkinsonism syndromes excluding PD
-Patients who could not perform the tests. 3-Women who were or might be
pregnant, who did not practice effective contraception and were of
childbearing potential, or who were breastfeeding
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note